Infliximab, a chimeric monoclonal anti-TNF-alfa agent used to treat autoimmune diseases, has shown a paradoxical side effect in the development of autoimmunity. We describe a case of alopecia areata universalis associated with infliximab treatment in a patient with Behçet disease. This case suggests a complex and contradictory role of TNF-α in the pathogenesis of alopecia areata. © 2010 Dermatology Online Journal.
Alopecia areata universalis during off-label treatment with Infliximab in a patient with Behçet disease / Beccastrini, E.; Squatrito, D.; Emmi, G.; Fabbri, P.; Emmi, L.. - In: DERMATOLOGY ONLINE JOURNAL. - ISSN 1087-2108. - ELETTRONICO. - 16:9(2010), pp. 15.--15.-.
Alopecia areata universalis during off-label treatment with Infliximab in a patient with Behçet disease
Emmi G.;Fabbri P.;
2010-01-01
Abstract
Infliximab, a chimeric monoclonal anti-TNF-alfa agent used to treat autoimmune diseases, has shown a paradoxical side effect in the development of autoimmunity. We describe a case of alopecia areata universalis associated with infliximab treatment in a patient with Behçet disease. This case suggests a complex and contradictory role of TNF-α in the pathogenesis of alopecia areata. © 2010 Dermatology Online Journal.Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
